Literature DB >> 23559661

Septic shock caused by Elizabethkingia meningoseptica: a case report and review of literature.

Su Hyeon Jung1, Boeun Lee, Aibek E Mirrakhimov, Nasir Hussain.   

Abstract

A 70-year-old woman, resident of a nursing home presented with complaints of fever for 1 day. Initial history, physical examination and laboratory tests were consistent with the diagnosis of systemic inflammatory response syndrome; blood culture from peripheral and central perm catheter were sent. Patient was started on empiric antibiotics and aggressive hydration. Blood cultures from peripheral access and central perm catheter grew Elisabethkingia meningoseptica on the second day. Patient was transferred to the intensive care unit for septic shock where patient needed vasopressors. Antibiotics were switched to intravenous trimethoprim-sulfamethoxazole, perm catheter was removed and catheter tip culture was sent. Catheter tip grew E meningoseptica (45 colony forming units). Patient showed excellent treatment response to intravenous trimethoprim-sulfamethoxazole and was weaned off pressors on day 4 with uneventful stay afterwards.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23559661      PMCID: PMC3645232          DOI: 10.1136/bcr-2013-009066

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with a totally implanted intravascular device.

Authors:  E Nulens; B Bussels; A Bols; B Gordts; H W Van Landuyt
Journal:  Clin Microbiol Infect       Date:  2001-07       Impact factor: 8.067

2.  FLAVOBACTERIUM MENINGOSEPTICUM IN ISRAEL.

Authors:  R SELIGMANN; M KOMAROV; R REITLER
Journal:  Br Med J       Date:  1963-12-14

3.  Studies on a group of previously unclassified bacteria associated with meningitis in infants.

Authors:  E O KING
Journal:  Am J Clin Pathol       Date:  1959-03       Impact factor: 2.493

4.  Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit.

Authors:  S N Hoque; J Graham; M E Kaufmann; S Tabaqchali
Journal:  J Hosp Infect       Date:  2001-03       Impact factor: 3.926

5.  Clinical features, antimicrobial susceptibilities, and outcomes of Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) bacteremia at a medical center in Taiwan, 1999-2006.

Authors:  M-S Hsu; C-H Liao; Y-T Huang; C-Y Liu; C-J Yang; K-L Kao; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-03       Impact factor: 3.267

6.  Susceptibilities of Chryseobacterium indologenes and Chryseobacterium meningosepticum to cefepime and cefpirome.

Authors:  P R Hsueh; L J Teng; P C Yang; S W Ho; K T Luh
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

7.  A Chryseobacterium meningosepticum outbreak observed in 3 clusters involving both neonatal and non-neonatal pediatric patients.

Authors:  Mehmet Ceyhan; Inci Yildirim; Alper Tekeli; Murat Yurdakok; Ebru Us; Belgin Altun; Tezer Kutluk; Ali Bülent Cengiz; Venhar Gurbuz; Cagri Barin; Arzu Bagdat; Duygu Cetinkaya; Deniz Gur; Onur Tuncel
Journal:  Am J Infect Control       Date:  2008-08       Impact factor: 2.918

8.  Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan.

Authors:  Yi-Tsung Lin; Cheng-Hsun Chiu; Yu-Jiun Chan; Mei-Lin Lin; Kwok-Woon Yu; Fu-Der Wang; Cheng-Yi Liu
Journal:  Scand J Infect Dis       Date:  2009

Review 9.  Community-acquired osteomyelitis caused by Chryseobacterium meningosepticum: case report and literature review.

Authors:  Chen-Hsiang Lee; Wei-Che Lin; Ju-Hsin Chia; Lin-Hui Su; Chun-Chih Chien; Ai-Hsiu Mao; Jien-Wei Liu
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-21       Impact factor: 2.803

10.  Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001).

Authors:  Jeffrey T Kirby; Helio S Sader; Timothy R Walsh; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more
  7 in total

1.  Multidrug resistant Elizabethkingia meningoseptica bacteremia - Experience from a level 1 trauma centre in India.

Authors:  Aishwarya Govindaswamy; Vijeta Bajpai; Vivek Trikha; Samarth Mittal; Rajesh Malhotra; Purva Mathur
Journal:  Intractable Rare Dis Res       Date:  2018-08

2.  Challenges in the identification of Chryseobacterium indologenes and Elizabethkingia meningoseptica in cases of nosocomial infections and patients with cystic fibrosis.

Authors:  É B de Carvalho Filho; F A L Marson; C E Levy
Journal:  New Microbes New Infect       Date:  2017-09-13

3.  Persistent Elizabethkingia meningoseptica bacteremia in a patient with multiple myeloma.

Authors:  Waleed Malik; Gavin McLeod
Journal:  IDCases       Date:  2019-08-05

4.  Candidate Animal Disease Model of Elizabethkingia Spp. Infection in Humans, Based on the Systematic Pathology and Oxidative Damage Caused by E. miricola in Pelophylax nigromaculatus.

Authors:  Xiaoli Huang; Yang Feng; Hong Tang; Guanqing Xiong; Liangyu Li; Yucen Yang; Kaiyu Wang; Ping Ouyang; Yi Geng; Defang Chen; Shiyong Yang
Journal:  Oxid Med Cell Longev       Date:  2019-09-18       Impact factor: 6.543

5.  Risk Factors for Mortality in Patients with Elizabethkingia Infection and the Clinical Impact of the Antimicrobial Susceptibility Patterns of Elizabethkingia Species.

Authors:  Hye Seong; Jung Ho Kim; Jun Hyoung Kim; Woon Ji Lee; Jin Young Ahn; Nam Su Ku M D; Jun Yong Choi; Joon Sup Yeom; Young Goo Song; Su Jin Jeong
Journal:  J Clin Med       Date:  2020-05-12       Impact factor: 4.241

6.  Elizabethkingia meningosepticum in a Patient with Six-Year Bilateral Perma-Catheters.

Authors:  Konstantin Boroda; Li Li
Journal:  Case Rep Infect Dis       Date:  2014-08-05

7.  Elizabethkingia miricola: A rare non-fermenter causing urinary tract infection.

Authors:  Parakriti Gupta; Kamran Zaman; Balvinder Mohan; Neelam Taneja
Journal:  World J Clin Cases       Date:  2017-05-16       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.